Literature DB >> 30925010

Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia.

Andrew Chang1, Michael Musk2, Melanie Lavender2, Jeremy Wrobel2,3, Meow-Chong Yaw2, Sharon Lawrence2, Shiji Chirayath2, Peter Boan1.   

Abstract

BACKGROUND: Invasive fungal infections (IFI) are common after lung transplantation with reported incidence of 8.1% to 16% at 12 months post-transplant, and 3-month all-cause mortality after IFI of 21.7%.
METHODS: We performed a retrospective study of IFI and fungal colonization in lung transplants (LTs) from November 2004 to February 2017.
RESULTS: 137 LTs were followed for a median 4.1 years (IQR 2.1-6.2 years). In addition to nebulized amphotericin for the transplant admission to all LTs, systemic mold-active azole was given to 80/130 (61.5%) LTs in the first 6 months post-transplant, 57/121 (47.1%) in the period 6-12 months after transplant, and 93/124 (75%) in the period more than 12 months post-transplant. Mold airways colonization was found in 81 (59.1%) LTs before and 110 (80.3%) LTs after transplantation. There were 13 IFIs for an overall incidence of 2.1 per 100 person-years, occurring at a median 583 days (IQR 182-1110 days) post-transplant, a cumulative incidence of 3.8% at 1 year, 7.6% at 3 years and 10.1% at 5 years post-transplant. All-cause 3-month mortality after IFI was 7.7%. Aspergillus species followed by Scedosporium apiospermum and Cryptococcus species were the commonest fungi causing IFI.
CONCLUSIONS: In our cohort the rate of IFI was comparatively low, likely because of comprehensive early antifungal use and preemptive therapy at any time after transplant. Prospective studies of fungal colonization late after LT are required to determine the risks and benefits of watchful waiting compared to preemptive therapy.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antifungal prophylaxis; fungal infection; invasive aspergillosis; lung transplant; lung transplantation; mold infection; preemptive antifungal therapy

Mesh:

Substances:

Year:  2019        PMID: 30925010     DOI: 10.1111/tid.13085

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  3 in total

1.  Molecular characterization of fungi causing colonization and infection in organ transplant recipients: A one-year prospective study.

Authors:  Fereshteh Zarei; Seyed Jamal Hashemi; Mohammadreza Salehi; Shahram Mahmoudi; Ensieh Zibafar; Zahra Ahmadinejad; Abbas Rahimi Foroushani; Pegah Ardi; Roshanak Daie Ghazvini
Journal:  Curr Med Mycol       Date:  2020

2.  Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients.

Authors:  Anna Apostolopoulou; Cornelius J Clancy; Abigail Skeel; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2021-10-02       Impact factor: 3.835

3.  Epidemiology and Antifungal Susceptibility Patterns of Invasive Fungal Infections (IFIs) in India: A Prospective Observational Study.

Authors:  Yubhisha Dabas; Immaculata Xess; Mragnayani Pandey; Jaweed Ahmed; Janya Sachdev; Azka Iram; Gagandeep Singh; Manoranjan Mahapatra; Rachna Seth; Sameer Bakhshi; Rakesh Kumar; Viveka P Jyotsna; Sandeep Mathur
Journal:  J Fungi (Basel)       Date:  2021-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.